LONDON--AstraZeneca PLC's (AZN.LN) Movantik drug has been
approved by the U.S. Food and Drug Administration, for the
treatment of constipation, in adult patients with chronic,
non-cancer pain, the U.K.-based pharmaceutical company said
Tuesday.
"The FDA approval of Movantik provides a new treatment option
for adult patients with chronic non-cancer pain suffering from
opioid-induced constipation, a common side effect of opioid
therapy," said Dr. Briggs Morrison, executive vice president,
global medicines development & chief medical officer,
AstraZeneca.
AstraZeneca said Movantik is expected to be available to
patients in the first half of 2015.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires